HYBRID EVENT: You can participate in person at Baltimore, Maryland, USA or Virtually from your home or work.
Regina Au, Speaker at Vaccine Research Conference
Oral Presentation (In-person)
Regina Au, BioMarketing Insight, United States

When the COVID-19 Vaccine was developed, time was crucial and the pharmaceutical and biotechnology  companies primary goal was to get a vaccine out as soon as possible so people to get vaccinated in saving lives.  What wasn't considered which most large companies co [....] » Read More

Daniel Becker, Speaker at Immunology Conferences
Oral Presentation (In-person)
Daniel Becker, KyooBe Tech GmbH, Germany

In the ongoing global Covid-19 aftermath, epidemics and pandemics triggered by microbial and viral pathogens remain a significant challenge for global vaccine production and worldwide supply. The Irradiation of target pathogens with low-energy electrons (LEEI) can reliably and [....] » Read More

Maduike Chiehiura Onwubiko Ezeibe, Speaker at Vaccine Research Conference
Oral Presentation (In-person)
Maduike Chiehiura Onwubiko Ezeibe, Michael Okpara University of Agriculture, Nigeria

Viral diseases, cancers (tumors) and antimicrobial resistant infections are among the world`s biggest health challenges. Literature reveals, that HIV and COVID-19 virus (RNA viruses) are positively charged while DNA viruses and abnormal (tumor/infected) cells are negatively charg [....] » Read More

Khursheed Anwer, Speaker at Vaccine Research Conference
Oral Presentation (In-person)
Khursheed Anwer, IMUNON, Inc., United States

This presentation describes the development of PLACCINE a novel DNA vaccine platform well-suited to overcome the limitations of the current vaccines.  The PLACCINE platform leverages the inherent DNA advantages including design flexibility incorporating multi-antigen payload [....] » Read More

Levast Benoit, Speaker at Vaccine Research Conference
Oral Presentation (In-person)
Levast Benoit, BIOASTER, France

The emergence of multiple SARS-CoV-2 variants as well as the implementation of different vaccination strategies gave rise to multiple immunization schemes in the population and related questions: which immunization strategy leads to the most effective long-term immune response ag [....] » Read More

Mayra Ramos Suzarte, Speaker at Vaccines Conferences
Keynote Presentation (In-person)
Mayra Ramos Suzarte, Center of Molecular Immunology, Cuba

Lung cancer is the first cause of death from cancer in the world and in some countries as the first cause of death for both sexes. Early diagnosis and timely therapy is successful for increasing the survival of these patients, however, the masking with frequent symptoms of other [....] » Read More

Mayra Ramos Suzarte, Speaker at Vaccines Conferences
Oral Presentation (In-person)
Mayra Ramos Suzarte, Center of Molecular Immunology, Cuba

COVID-19 continues to be a global health problem, it is a multifactorial disease characterized by a process of hyperinflammation. Itolizumab, a humanized anti-CD6 mAb, has the Emergency Use Authorization (UEA) for patients with this disease with signs of hyperinflammation. Method [....] » Read More

Ismail, Speaker at Vaccines Conferences
Oral Presentation (In-person)
Ismail, Globe Biotech ltd,Bangladesh, Bangladesh

The devastating novel coronavirus (COVID-19) pandemic worldwide has become a global health crisisThis disease is highly contagious and caused by the transmission of severe acute respiratory syndrome, coronavirus 2 (SARS-CoV-2). To prevent the transmission of SARS-CoV-2, disinfect [....] » Read More

Kristen Lee Moriarty, Speaker at Immunology Conferences
Oral Presentation (In-person)
Kristen Lee Moriarty, UCONN Health, United States

The National Institute of Health recommends Nirmatrelvir-Ritonavir (NIR) treatment for pregnant patients with COVID-19. However, little is known about NIR treatment acceptance rates in pregnant patients and what strategies may increase access and acceptance rates of NIR treatment [....] » Read More

Massimo Florio, Speaker at Vaccine Research Conference
Oral Presentation (In-person)
Massimo Florio, University of Milan, Italy

This study provides a mapping of funds contributed by different actors for the R&D and the expansion of the production capacity of COVID-19 vaccines, with a focus on those authorised in the EU. Nine vaccines are examined. It is found that governments, mainly the US (with some [....] » Read More

Paul Van Buynder, Speaker at Immunology Conferences
Oral Presentation (Virtual)
Paul Van Buynder, Griffith University, Australia

Immune senescence and inflammaging render older persons more susceptible to severe consequences of infectious diseases and likely to exhibit poorer responses to vaccination.  Older persons need influenza, pneumococcal, herpes zoster, pertussis and SARS-CoV-2 vaccines and soo [....] » Read More

Indira Acharya, Speaker at Vaccines Conferences
Oral Presentation (Virtual)
Indira Acharya, Medstar, United States

however ANA, rheumatoid factor Reactive arthritis after various vaccinations has been previously described but such kind of reaction after mpox vaccination has not been previously reported. Here we present a case of recently diagnosed reactive arthritis following intradermal mpox [....] » Read More

Nzolameso Makaya Jennifer, Speaker at Immunology Conferences
Poster Presentation (In-person)
Nzolameso Makaya Jennifer, Hopital General De Reference De Kimbanseke Pierre Pokom, Congo

70% of people over 65 are hypertensive; high blood pressure increases the risk of exposure to cardiovascular disease (myocardial infarction and heart failure) and stroke. This is a public health problem, given the aging of the population. There are few studies carried out in e [....] » Read More

Lev Ramirez, Speaker at Immunology Conferences
Poster Presentation (In-person)
Lev Ramirez, Universidad de La Sabana , Colombia

In the wake of the COVID-19 pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2), the global healthcare landscape has undergone a profound transformation. This transformation has been marked by the rapid development and deployment of COVID-19 vaccines [....] » Read More

Olivia Viscuso, Speaker at Vaccines Conferences
Poster Presentation (Virtual)
Olivia Viscuso, Mccombs School of Business at the University of Texas at Austin, United States

Introduction In recent years, politics and business have become increasingly intertwined, with employees increasingly seeking workplaces that align with their political views (Stuckatz, 2020). The COVID-19 pandemic response introduced public health regulations that became cont [....] » Read More

Joe Smyser, Speaker at Immunology Conferences
Keynote Presentation (Virtual)
Joe Smyser, The Public Good Projects, United States

Introduction: As the pandemic evolves and nations refocus on routine immunizations and vaccine-preventable outbreaks, it is critical to continue increasing vaccine demand. Misinformation threatens the success of vaccination programs across the world. Since 2017, The Public Good P [....] » Read More

Sudhakar Bangera, Speaker at Vaccines Conferences
Keynote Presentation (Virtual)
Sudhakar Bangera, Fellow-vaccinology managing partner AILEEN clinical research services AILEEN, India

It’s not just the bacteria or viruses that most commonly cause life-threatening disease in human, some of them could be fungal pathogens. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infe [....] » Read More

Sushmita Koley, Speaker at Vaccines Conferences
Oral Presentation (In-person)
Sushmita Koley, Senior Scientist Bio-Rad Laboratories, United States

One of the crucial steps in deploying plasma therapy for COVID-19 has been the development of critical assays to detect SARS-CoV-2 antibodies and evaluate their potential suitability. Unfortunately, assays that assess neutralizing antibodies involve use of live SARS-CoV-2 virus i [....] » Read More

Bethan Charlotte Hussey, Speaker at Immunology Conferences
Oral Presentation (Virtual)
Bethan Charlotte Hussey, UK Health Security Agency, United Kingdom

The UK Health Security Agency (UKHSA) has longstanding expertise in the technological support of vaccine development through a vast array of immunological assays. In early 2020, using this valuable knowledge, scientists within UKHSA were able to rapidly develop a live virus micro [....] » Read More

Brandon Lucke Wold, Speaker at Vaccine Research Conference
Oral Presentation (Virtual)
Brandon Lucke Wold, Baylor University, United States

Neonatal sepsis is a bloodstream infection that affects newborn infants under the age of 28 days and is a leading cause of morbidity and mortality in these children 1,2. There is little information on the prevalence of newborn sepsis, however Fleischmann-Struzek et al. estim [....] » Read More

Nsana Sjelin Nardiouf, Speaker at Vaccine Research Conference
Oral Presentation (Virtual)
Nsana Sjelin Nardiouf, Université Paris Cité, France

The insecticide-treated mosquito net is one of the preventive tools in the fight against malaria vectors in the Republic of Congo. The general objective of this study was to assess the impact of the use of long-acting insecticide-treated mosquito nets in the strategy for the cont [....] » Read More

Joana Kira Besecke, Speaker at Vaccine Research Conference
Poster Presentation (Virtual)
Joana Kira Besecke, Fraunhofer Institute for Organic Electronics, Germany

The use of low-energy electron irradiation (LEEI) is a novel and highly efficient method for manufacturing vaccines and other pharmaceutical products. This technology provides advantages against conventional methods for virus inactivation, as the process is faster, does not requi [....] » Read More

Sonal Gidwani, Speaker at Vaccines Conferences
Poster Presentation (Virtual)
Sonal Gidwani, Calder Biosciences Inc, United States

Viral fusion proteins enable cellular infection by fusing viral and cellular membranes accompanied by their transition from the pre-fusion to the post-fusion conformation during viral entry.  Fusion proteins in their prefusion conformation elicit high neutralizing antibodies [....] » Read More

Devarshi Brahmbhatt, Speaker at Vaccines Conferences
Poster Presentation (Virtual)
Devarshi Brahmbhatt, Calder Biosciences Inc, United States

Viral fusion proteins enable cellular infection by fusing viral and cellular membranes accompanied by their transition from the pre-fusion to the post-fusion conformation during viral entry.  Fusion proteins in their prefusion conformation elicit high neutralizing antibodies [....] » Read More

Diego Tomassone, Speaker at Vaccine Research Conference
Poster Presentation (Virtual)
Diego Tomassone, Holos medica clinical and research, Italy

Recent advances in genomic and bioinformatic technologies have enabled the emergence of the field of immunogenomics. This intersection of immunology and genetics has expanded our understanding of how the immune system responds to infection and vaccination. While the immunogenetic [....] » Read More

Solange Whegang Youdom, Speaker at Vaccine Research Conference
Poster Presentation (Virtual)
Solange Whegang Youdom, University of Dschang, Cameroon

Complete childhood vaccination remains poor in Sub-Saharan African countries. Although missed opportunity for vaccination (MOV) was found responsible for low coverage, median time-to-corrected is useful to assess delay in vaccination. MOV also reflects quality of immunization ser [....] » Read More

Watsapp